Hepatitis web study H EPATITIS W EB S TUDY H EPATITIS C O NLINE Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: November 18, 2014

Hepatitis web study Hepatitis web study Background and Dosing 3D (P ARITAPREVIR -R ITONAVIR -O MBITASVIR + D ASABUVIR )

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) Approval Status: submitted for FDA approval on April 21, 2014 Proposed Indication for Chronic HCV Monoinfection - GT 1 - Duration 12 to 24 weeks (with or without ribavirin) Class & Mechanism - Paritaprevir (ABT-450): NS3/4A serine protease inhibitor - Ritonavir: HIV protease inhibitor used as pharmacologic booster - Ombitasvir (ABT-267): NS5A inhibitor - Dasabuvir (ABT-333): Nonnucleoside NS5B polymerase inhibitor Dose: Paritaprevir-Ritonavir-Ombitasvir (fixed dose 150/100/25 mg once daily) plus Dasabuvir 250 mg twice daily Adverse Effects (AE): fatigue, insomnia Wholesaler Acquisition Cost in United States: NA

Hepatitis web study Hepatitis web study Treatment Naive - SAPPHIRE-I: 3D + RBV for 12 weeks in GT1 - PEARL-III and PEARL-IV: 3D +/- RBV for 12 weeks in GT1 Treatment Experienced - SAPPHIRE-II: 3D + RBV for 12 weeks in GT1 - PEARL-II: 3D +/- RBV for 12 weeks in GT1b Treatment Naive - SAPPHIRE-I: 3D + RBV for 12 weeks in GT1 - PEARL-III and PEARL-IV: 3D +/- RBV for 12 weeks in GT1 Treatment Experienced - SAPPHIRE-II: 3D + RBV for 12 weeks in GT1 - PEARL-II: 3D +/- RBV for 12 weeks in GT1b Summary of Key Phase 3 Studies 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV

Hepatitis web study Hepatitis web study Summary of Key Studies in Special Populations 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV Compensated Cirrhosis: Treatment Naïve/Experienced - TURQUOISE-II: 3D + RBV for 12 or 24 weeks in GT1 HIV Coinfection: Treatment Naïve/Experienced - TURQUOISE-I: 3D + RBV for 12 or 24 weeks in GT1 Post- Liver Transplantation Recipients - CORAL-I: 3D + RBV for 24 weeks in GT1 Compensated Cirrhosis: Treatment Naïve/Experienced - TURQUOISE-II: 3D + RBV for 12 or 24 weeks in GT1 HIV Coinfection: Treatment Naïve/Experienced - TURQUOISE-I: 3D + RBV for 12 or 24 weeks in GT1 Post- Liver Transplantation Recipients - CORAL-I: 3D + RBV for 24 weeks in GT1

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et al. N Engl J Med. 2014;370:

Hepatitis web study Source: Feld JJ, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Design

Hepatitis web study Source: Feld JJ, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Study Regimens Group A N = 473 3D + Ribavirin Placebo SVR12 3D + Ribavirin SVR12 Double blind Open label (data pending) Group B N = 158 Week D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg)

Hepatitis web study Source: Feld JJ, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Baseline Characteristics Baseline Characteristic Group A (n=473) Group B (n=158) Age (years), Mean Male sex % Race (%) White Black Other Body Mass Index (Mean) HCV genotype (%) 1a 1b IL28B CC genotype, (%) HCV RNA, log 10 IU/ml Fibrosis score ≥ F

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Results SAPPHIRE-I: SVR12 in Group A (3D + Ribavirin) Source: Feld JJ, et al. N Engl J Med. 2014;370: /473307/322148/151

Hepatitis web study Source: Feld JJ, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Adverse Events During Double-Blind Phase NUTRINO: SVR 12 by Liver Disease Event Group A = 3D + RBV (n=473) Group B = Placebo (n=158) Any adverse event (%) Any adverse event leading to discontinuation of study drug (%) 0.6 Any serious adverse event2.10 Grade 3 or 4 lab abnormality (%) Alanine aminotransferase Aspartate aminotransferase Alkaline phosphatase00 Total bilirubin2.80 Hemoglobin00

Hepatitis web study Source: Feld JJ, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study: Conclusions Conclusions: “In previously untreated patients with HCV genotype 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT- 450/r–ombitasvir and dasabuvir with ribavirin was highly effective and was associated with a low rate of treatment discontinuation.” Note: ABT-450/r = Paritaprevir-Ritonavir

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV Phase 3 Treatment Naïve Ferenci P, et al. N Engl J Med. 2014;370:

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Study Design

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Study Regimens HCV Genotype 1a n = 100 3D + Ribavirin SVR12 n = 205 3D + Placebo SVR12 HCV Genotype 1b n = 210 3D+ Ribavirin SVR12 n = 209 3D + Placebo SVR12 Week D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg)

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Baseline Characteristics Baseline Characteristic Genotype 1aGenotype 1b 3D + RBV (n=100) 3D (n=205) 3D + RBV (n=210) 3D (n=209) Age, years Male sex (%) BMI kg/m Race (%) White Black Other IL28B CC (%) Metavir F3 (%)16.0%18.5%10.5%9.6% HCV RNA log 10 IU/ml

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Results Genotype 1aGenotype 1b 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir; RBV = Ribavirin 97/100185/205209/210207/209

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Adverse Events Event GT1aGT1b 3D + RBV (n=100) 3D ( n=205) 3D+RBV (n=210 ) 3D (n=209) Any adverse event % Any serious adverse event % Common adverse events: Headache % Fatigue % Pruritus % Nausea % Insomnia % Diarrhea % Laboratory abnormalities: Hemoglobin < 10 g/dl % Total bilirubin > 3x ULN %

Hepatitis web study Source: Ferenci P, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV: Conclusions Conclusions: “Twelve weeks of treatment with ABT-450/r–ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection. Rates of virologic failure were higher without ribavirin than with ribavirin among patients with genotype 1a infection but not among those with genotype 1b infection.” Note: ABT-450/r = Paritaprevir-Ritonavir

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-II Phase 3 Treatment Experienced Zeuzem S, et al. N Engl J Med. 2014;370:

Hepatitis web study Source: Zeuzem S, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II: Study Design

Hepatitis web study Source: Zeuzem S, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II: Regimens Active N = 297 3D + Ribavirin Placebo SVR12 3D + Ribavirin SVR12 Double blind Open label (data pending) Placebo N = 97 Week D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg)

Hepatitis web study Source: Zeuzem S, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II Study: Baseline Characteristics Baseline Characteristic 3D + RBV (n=297) Placebo Arm (n=97) Age (years), Mean Male sex % Race (%) White Black Asian Body Mass Index (Mean) HCV genotype (%) 1a 1b IL28B CC genotype, (%) Type of Prior Response Relapse Partial Response Null Response HCV RNA, log 10 IU/ml (mean) Fibrosis score F2 or F3 (%)

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II: Results SAPPHIRE-II: Results by Genotype 1 Subtype Source: Zeuzem S, et al. N Engl J Med. 2014;370: /297166/173119/123

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II: Results SAPPHIRE-II: Results by Prior Treatment Response Source: Zeuzem S, et al. N Engl J Med. 2014;370: /29782/8665/65139/146

Hepatitis web study Source: Zeuzem S, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II Study: Key Adverse Events Event 3D + RBV (n=297) Placebo (n=97) Any adverse events % Any serious adverse event % Common adverse events: Headache % Fatigue % Nausea % Asthenia % Insomnia % Pruritus % Diarrhea % Dyspnea % Cough % Myalgia % Abnormalities in laboratory values of grade 3 or 4 % Alanine aminotransferase Total bilirubin2.40

Hepatitis web study Source: Zeuzem S, et al. N Engl J Med. 2014;370: D (Paritaprevir-Ritonavir-Ombitasvir) + Dasabuvir + RBV in GT1 SAPPHIRE-II: Conclusions Conclusions: “Rates of response to a 12-week interferon-free combination regimen were more than 95% among previously treated patients with HCV genotype 1 infection, including patients with a prior null response.”

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II Phase 3 Treatment Experienced Andreone P, et al. Gastroenterology. 2014;147:

Hepatitis web study Source: Andreone P, et al. Gastroenterology. 2014;147: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Study Design

Hepatitis web study Source: Andreone P, et al. Gastroenterology. 2014;147: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Regimens N =14 n = 91 3D + Ribavirin SVR12 n = 95 3D SVR12 Week D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg)

Hepatitis web study Source: Andreone P, et al. Gastroenterology. 2014;147: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Baseline Characteristics Baseline Characteristic 3D + RBV (n=91) 3D (n=95) Age (years), Mean54.2 Male sex % Race (%) White Black Body Mass Index (Mean) Previous Response to PEG + RBV Null responder Partial responder Relapser IL28B Non-CC genotype, (%) HCV RNA, log 10 IU/ml (mean) Fibrosis score F3 (%)

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Results PEARL-II: SVR 12 Rates* Source: Andreone P, et al. Gastroenterology. 2014;147: /8891/91 *Primary endpoint by intention-to-treat analysis 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir

Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Results by Prior Treatment Response PEARL-II: Results by Prior Treatment Response Source: Andreone P, et al. Gastroenterology. 2014;147: /8891/9129/3132/3224/2526/2632/3233/33

Hepatitis web study Source: Andreone P, et al. Gastroenterology. 2014;147: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Treatment-Emergent Adverse Effects Event 3D + RBV (n=91) 3D (n=95) Any Treatment Emergent Adverse Effect % Any serious Treatment Emergent Adverse Effect %2.20 Common adverse events: Fatigue % Headache % Nausea % Insomnia % Pruritus % Diarrhea % Asthenia % Anemia %11.00 Blood bilirubin level increased %8.80 Rash % Laboratory abnormalities: Hemoglobin (< lower limit of normal at end of treatment), % Total bilirubin > 3x ULN8.80

Hepatitis web study Source: Andreone P, et al. Gastroenteroly. 2014;147: D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1b PEARL-II: Conclusions Conclusions: “The interferon-free regimen of ABT-450, ritonavir, ombitasvir, and dasabuvir, with or without ribavirin, produces a high rate of SVR12 in treatment-experienced patients with HCV genotype 1b infection. Both regimens are well tolerated, as shown by the low rate of discontinuations and generally mild adverse events.” Note: ABT-450 = Paritaprevir

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-II Phase 3 Treatment Naïve and Treatment Experienced Poordad F, et al. N Engl J Med. 2014;370: Compensated Cirrhosis

Hepatitis web study Source: Poordad F, et al. N Engl J Med. 2014;370: D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Study Design

Hepatitis web study Source: Poordad F, et al. N Engl J Med. 2014;370: D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Regimens Group A N = 208 3D + Ribavirin SVR12 Group B N = 172 3D = Paritaprevir-ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Week

Hepatitis web study 3D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Results TURQUOISE II: SVR12 by Genotype 1 Subtype Source: Poordad F, et al. N Engl J Med. 2014;370: /208165/172124/140114/12167/6850/51

Hepatitis web study 3D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Results TURQUOISE II: SVR12 Based on Prior Treatment Source: Poordad F, et al. N Engl J Med. 2014;370: /8670/7428/2923/2317/1813/1365/7559/62

Hepatitis web study 3D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Results for GT1a TURQUOISE II: Genotype 1a SVR12 Based on Prior Treatment Source: Poordad F, et al. N Engl J Med. 2014;370: /6452/5614/1513/1311/1110/1040/5039/42

Hepatitis web study 3D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Results for GT1b TURQUOISE II: Genotype 1b SVR12 Based on Prior Treatment Source: Poordad F, et al. N Engl J Med. 2014;370: /2218/1814/1410/106/73/325/2520/20

Hepatitis web study Source: Poordad F, et al. N Engl J Med. 2014;370: D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Adverse Effects Event 3D + RBV x 12 weeks (n=208) 3D + RBV x 24 weeks (n=172) Any adverse event (%) Adverse event leading to stopping study drug (%) Any serious adverse event Most common adverse event Fatigue (%) Headache (%) Nausea (%) Pruritis (%) Insomnia (%) Diarrhea (%) Asthenia (%) Rash (%) Irritability (%) Anemia (%) Dyspnea (%)

Hepatitis web study Source: Poordad F, et al. N Engl J Med. 2014;370: D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Adverse Effects Lab Abnormalities 3D + RBV x 12 weeks (n=208) 3D + RBV x 24 weeks (n=172) Alanine aminotransferase, grade 3 or 46 (2.9)0 Aspartate aminotransferase, grade 3 or 41 (0.5)0 Alkaline phosphatase, grade 3 or 400 Total bilirubin, grade 3 or 428 (13.5)9 (5.2) Hemoglobin Grade 1 Grade 2 Grade 3 Grade (49.5) 12 (5.8) 2 (1) 1 (0.5) 97 (56.4) 18 (10.5) 1 (0.6) 0

Hepatitis web study Source: Poordad F, et al. N Engl J Med. 2014;370: D + Ribavirin in GT1 and Compensated Cirrhosis TURQUOISE-II: Conclusions Conclusions: “In this phase 3 trial of an oral, interferon-free regimen evaluated exclusively in patients with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antiviral agents and ribavirin resulted in high rates of sustained virologic response. Drug discontinuations due to adverse events were infrequent.”

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 TURQUOISE-I Phase 2 Treatment Naïve and Treatment Experienced Wyles D, et al. 65 th AASLD. 2014: Abstract HIV Coinfection

Hepatitis web study Source: Wyles D, et al. 65 th AASLD. 2014: Abstract D + Ribavirin for HCV-HIV Coinfection and GT1 TURQUOISE-I: Part 1 Study Design

Hepatitis web study Source: Wyles D, et al. 65 th AASLD. 2014: Abstract D + Ribavirin for HCV-HIV Coinfection and GT1 TURQUOISE-I: Part 1 Study Regimens N = 31 3D + Ribavirin 3D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) 3D + Ribavirin SVR12 N = 32 Week

Hepatitis web study Source: Wyles D, et al. 65 th AASLD. 2014: Abstract D + Ribavirin for HCV-HIV Coinfection and GT 1 TURQUOISE-I: Patient Population Baseline Characteristic 12-Week Arm (n=31) 24-Week Arm (n=32) Age (years), Mean50.9 Male sex %9491 Black Race (%)2325 Cirrhosis (%)19 HCV genotype (%) 1a 1b HCV RNA, log 10 IU/ml (mean) IL28B non-CC genotype, (%)8478 Previous Response to PEG + RBV Naïve Relapse Partial response Null response CD4 Count, cells/mm 3 (mean)633625

Hepatitis web study 3D + Ribavirin for HCV-HIV Coinfection and GT 1 TURQUOISE-I: Part 1 Results TURQUOISE-I: SVR Rates (to date) Source: Wyles D, et al. 65 th AASLD. 2014: Abstract D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir 29/31 30/3229/32

Hepatitis web study 3D + Ribavirin for HCV-HIV Coinfection and GT 1 TURQUOISE-I: Part 1 Results Details of Five Patients NOT Achieving SVR 12 Source: Wyles D, et al. 65 th AASLD. 2014: Abstract /31 30/3229/32 One patient in 12-week arm withdrew consent prior to finishing treatment; had undetectable HCV RNA at week 10 One patient in 12-week arm had virologic relapse at week 4 post treatment; had new resistant HCV variants at 3 viral targets (D168V in NS3/4A, M28T in NS5A, and S556G in NS5B) One patient in 24-week arm had virologic breakthrough during treatment; had new resistant HCV variants at 3 viral targets (R155K in NS3/4A, Q30R in NS5A, and S556G in NS5B) Two patients in 24-week arm achieved early SVR but appeared to be reinfected with GT1a isolate distinct from baseline HCV isolate; both patients had engaged in high-risk sexual activity post treatment

Hepatitis web study Hepatitis web study 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Phase 2 Treatment Naïve and Treatment Experienced Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] Liver Transplantation

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Study Design

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Regimen N = 34 3D + Ribavirin SVR12 Week D = Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing 3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily) + Dasabuvir: 250 mg twice daily Ribavirin (RBV): dosing managed per investigator discretion; most patients received mg/day

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Baseline Characteristics Baseline Characteristic3D + Ribavirin (n=34) Age (years), Mean59.6 Male sex–no. (%)27 (79) Race–no. (%) White Black Multiple 29 (85) 4 (12) 1 (3) Body Mass Index (kg/m 2 ) Mean29.7 HCV genotype–no. (%) 1a 1b 29 (85) 5 (15) IL28B, non-CC genotype–no. (%)26 (76) HCV RNA, log 10 IU/ml6.6 Fibrosis stage (%) F0 F1 F2 6 (18) 13 (38) 15 (44)

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Results 34/34 On Treatment 33/34 After Treatment

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Adverse Events Adverse Event Occurring in > 15% of the 34 Patients Receiving 3D + RBV EventN (%) Any adverse event33 (97) Fatigue17 (50) Headache15 (44) Cough11 (32) Anemia10 (29) Diarrhea9 (26) Insomnia9 (26) Asthenia8 (24) Nausea8 (24) Muscle spasms7 (21) Rash7 (21) Back pain6 (18) Dizziness6 (18) Peripheral edema6 (18 Rhinorrhea6 (18)

Hepatitis web study Source: Kwo PY, et al. N Engl J Med November 11. [Epub ahead of print] 3D + RBV in Liver Transplant Recipients with Recurrent HCV GT1 CORAL-I Trial: Conclusions Conclusions: “Treatment with the multitargeted regimen of ombitasvir- ABT-450/r and dasabuvir with ribavirin was associated with a low rate of serious adverse events and a high rate of sustained virologic response among liver-transplant recipients with recurrent HCV genotype 1 infection, a historically difficult-to-treat population.” Note: ABT-450/r = Paritaprevir-Ritonavir

Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention.